Impress employers and recruiters.
Choose from hundreds of resume examples.

Target Resume Now

About the Role

The Director, Controller will build and run the financial infrastructure of a fast-moving clinical-stage biotechnology company. This individual will own day-to-day accounting operations and related internal controls, including month-end, quarter-end, and year-end close processes, and lead necessary system implementations to support the Company’s continued growth. This is a hands-on role that will collaborate with various internal and external partners.

Responsibilities

Own the monthly, quarterly, and annual close process to ensure accurate financial statements on a timeline that meets internal and external reporting deadlines.
Oversee the majority of GL accounts including Cash, Prepaids, R&D and clinical trial accruals, and G&A accruals.
Develop and own the clinical trial accrual process including reviewing clinical contracts, CRO reports, patient costs, site costs, and invoices for timely and proper accrual.
Liaise directly with clinical vendors to ensure completeness and accuracy.
Manage accounts payable and cash disbursements to ensure timely and accurate payments to our vendors.
Supervise and review multi-state payroll process (semi-monthly) to ensure all employees are paid timely and accurately.
Coordinate with FP&A to support their budgeting and forecasting needs and their creation of budget vs actuals, including ensuring timely and accurate reporting of actuals.
Develop and maintain accounting policies, procedures, and internal controls that can scale through an IPO and beyond.
Evaluate, implement, and optimize financial systems, including Netsuite and a new payroll system.
Coordinate with legal and HR on tax compliance and regulatory filings.
Support relationships with external accounting, tax, and payroll service providers.
Assist in the hiring and development of a small, high-performing accounting and finance team as the company scales.

Requirements

8-12 years of progressive finance and accounting experience, with at least 5 years at a publicly traded or pre-IPO biotech or life sciences company.
Deep technical accounting knowledge (US GAAP), including R&D accruals, clinical trial accounting, and pre-clinical/clinical stage company financials.
Demonstrated experience building or significantly scaling accounting and finance functions at a clinical-stage company.
Prior experience supporting or executing a public offering (IPO, follow-on, crossover) preferred.
Strong knowledge of public company requirements, including SEC reporting, internal controls (SOX), financial planning, and cross-functional alignment.
Experience managing Big 4 or national firm audits.
CPA preferred; public accounting background preferred.
Excellent judgment, high integrity, and the ability to operate with minimal overhead in a fast-moving environment.
The right candidate thrives in a nimble environment, brings public company rigor to a private-stage company, and can build scalable systems without adding unnecessary overhead.
Strong written and verbal communication skills with a collaborative, team-oriented approach.
Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity.
Flexible, proactive, and hands-on mindset with a roll-up-your-sleeves, can-do attitude.

Skills

US GAAP
R&D accruals
Clinical trial accounting
Pre-clinical/clinical stage company financials
SEC reporting
Internal controls (SOX)
Financial planning
Netsuite
Payroll systems
Written communication
Verbal communication

Location

Remote

Work Type

Full-time

Experience Level

Director

Education Level

CPA preferred

Salary/Compensations

$200,000 - $240,000

Benefits

Annual bonus
Equity
Comprehensive benefits offering

About the Company

Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases.
Our lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Braveheart’s goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, reversibility and reducing prescribing complexity.
With a proven leadership team, a strong financial foundation, and a high-value late-stage asset, Braveheart Bio represents an outstanding opportunity for ambitious, mission-driven professionals to make a tangible impact in a high-profile and rapidly evolving therapeutic area.

Equal Opportunity

We are an equal opportunity employer.
We are committed to inclusion and diversity, and we do not discriminate on the basis of race, gender, religion, gender, sexual orientation, age, color, marital status, veteran status, disability status, national origin, or any characteristic protected under applicable law.
Braveheart participates in the federal E‑Verify program to confirm employment authorization for all new hires.